antidiabetic drug

2. MECHANISM
OF ACTION

3. MECHANISM
OF ACTION

4. PHARMACOLOGICAL EFFECTS
•POSTPRANDIAL GLUCOSE LEVELS IS REDUCED BOTH IN NORMAL
AND DIABETIC SUBJECTS, SO CREATING AN INSULIN SPARING
EFFECT.
•THE EFFICACY OF THE DRUGS IS SMALL.
•HYPOGLYCEMIA DOES NOT OCCUR EVEN IN OVERDOSAGE.

5. PHARMACOKINETICS
•ORAL BIOAVAILABILITY: ACARBOSE 2%; MIGLITOL >90%
•ELIMINATION: MIGLITOL > 90% BY THE KIDNEY

6. CONTRA-INDICATIONS AND CAUTIONS
•INFLAMMATORY BOWEL DISEASE
•GASTROINTESTINAL CONDITIONS WORSENED BY GAS OR DISTENSION
•RENAL DISEASE

7. THERAPEUTIC USES
•TYPE II DIABETES AS MONOTHERAPY OR IN COMBINATION WITH SULFONYLUREAS OR
INSULIN.
•AS MONOTHERAPY IN ELDERLY PATIENTS OR IN PATIENTS WITH PREDOMINANTLY
POSTPRANDIAL HYPERGLYCEMIA.
•NOTE: IF HYPOGLYCEMIA OCCURS WHEN ADMINISTERED WITH INSULIN OR
SULFONYLUREAS, ORAL ADMINISTRATION OF SUGARS OTHER THAN GLUCOSE IS
INEFFECTIVE.

8. ALPHA GLUCOSIDASE INHIBITORS